Mucosat-Belmed solution for intramuscular injection 100mg/ml in ampoules 1ml №5×2

Name:
Mukosat-Belmed solution for and 1ml in cont. cell pack. No. 10
Description:
Transparent colorless or slightly yellowish solution, with the smell of benzyl alcohol. The main active ingredient Chondroitin sulfate Release form Solution Dosage 100 mg / ml. Pharmacological action The drug has an anti-inflammatory, analgesic effect. Suppresses the activity of enzymes that cause degradation of articular cartilage. Anti-inflammatory and analgesic effects are achieved by reducing the release of inflammatory mediators and pain factors into the synovial fluid through synoviocytes and macrophages of the synovial membrane, as well as by suppressing the secretion of leukotriene B4 and prostaglandin E2. The use of the drug prevents the compression of cartilage tissue, acts as a lubricant for articular surfaces, normalizes the production of joint fluid, improves joint mobility, and helps to reduce pain intensity. Indications for use Relief of symptoms (from mild to moderate pain), with a gradual development of the effect, with adequately diagnosed osteoarthritis of the knee, hip joints, osteochondrosis of the spine. Dosage and administration The drug is intended for intramuscular injection. Do not administer intravenously. adult and elderly patients. The drug is administered intramuscularly in 1 ml every other day. With good tolerance, the dose is increased to 2 ml, starting with the fourth injection. The course of treatment is 25-35 injections. Repeat courses? in 6 months. Application in children. Do not use in children. Use during pregnancy and lactation Use of the drug during pregnancy and lactation is contraindicated. Influence on the ability to drive vehicles and other potentially dangerous mechanisms Does not affect. Precautions If allergic reactions or hemorrhages occur, treatment should be discontinued. To achieve a stable clinical effect, at least 25 injections of the drug Mukosat-Belmed are required, but the effect persists for a long time for many months after the end of the course of treatment. 1 ml of the solution contains 9 mg of benzyl alcohol, which can cause poisoning and pseudo-anaphylactic reactions in infants and children under 3 years of age. Interaction with other drugs When combined with non-steroidal anti-inflammatory drugs, Mukosat-Belmed allows you to reduce the dose of non-steroidal anti-inflammatory drugs. The drug enhances the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics, which requires more frequent monitoring of blood coagulation parameters when used together. Contraindications Hypersensitivity to any of the components of the drug, a tendency to bleeding, thrombophlebitis, pregnancy, lactation (for the duration of treatment, breastfeeding should be stopped). Children under 15 years of age (efficacy and safety have not been established). With caution: in case of blood clotting disorders, diabetes mellitus, in people with increased body weight, in patients receiving a low-salt diet, children under 18 years of age, with impaired renal function, in women planning pregnancy. Composition Per ampoule: active substance: chondroitin sulfate? 100.0 mg; excipients: benzyl alcohol, water for injection. Overdose The drug does not show toxicity even with a significant overdose. Symptoms: allergic reactions, hemorrhages at the injection site. In case of accidental acute overdose? symptomatic treatment. All activities are carried out against the backdrop of the withdrawal of the drug Mukosat-Belmed. Side effect On the part of the skin and subcutaneous fat: there are reports of cases of erythema, urticaria, eczema, maculopapular rash, accompanied or not accompanied by itching and / or swelling. From the gastrointestinal tract: rare cases of nausea, vomiting have been reported. From the immune system: very rare cases of angioedema have been reported. Cases of bleeding at the injection site are noted. Reporting adverse reactions If you experience any adverse reactions, please consult your physician. This also applies to any side effects not listed in this package insert. You can also report adverse reactions to the information database on adverse reactions (actions) to drugs, including reports of drug inefficiency detected in the state (UE “Center for Expertise and Testing in Healthcare M3 RB”, website rceth.by) . By reporting adverse reactions, you help to get more information about the safety of the drug. Storage conditions In a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Mukosat-Belmed solution for intramuscular injection 100mg/ml in ampoules 1ml №5×2 /ml in ampoules 1ml №5×2